

CRYSTAL STRUCTURE ANALYSIS OF ETHYL4-[4-HYDROXY-3-METHOXYPHENYL]-6- METHYL-2-THIOXO-1,2,3,4- TETRAHYDROPYRIMIDINE-5- CARBOXYLATE

¹J. Josephine Novina, ²G. Vasuki, ³M. Suresh, ⁴Vijiayan Viswanathan, ¹M. Saranya

¹Department of Physics, Idhaya College for Women, Kumbakonam, India

²Department of Physics, Kunthavai Naachiar Government Arts College (W), Thanjavur, India.

³Department of Chemistry, L.N Government College, Ponneri, Thiruvallur, India.

⁴Centre of advanced study in crystallography and Biophysics, University of Madras,
Guindy campus. Chennai-25.

Abstract: The title compound crystallizes in the triclinic space group $P\bar{1}$, with $a = 8.474(5)$ Å, $b = 9.402(5)$ Å, $c = 11.239(5)$ Å, $\alpha = 98.133(5)^\circ$, $\beta = 108.117(5)^\circ$, $\gamma = 108.575(5)^\circ$, $V = 777.4(7)$ Å³ and the number of molecules in the unit cell $Z = 2$. In the title compound, C₁₅H₁₈N₂O₄S, the dihydropyrimidine ring adopts a boat conformation. The dihedral angle between the benzene and tetrahydropyrimidine is $80.29(8)^\circ$. In the crystal, molecules are linked via pairs of C—H...S hydrogen bonds, forming inversion dimers with an R₂²(12) ring motif. The crystal structure is further stabilized by an intramolecular C—H...O hydrogen bonds forming a closed six membered ring.

Keywords – tetrahydropyrimidine, intermolecular, ring motif, hydrogen bonds.

I. INTRODUCTION

Pyrimidines are the most important six membered heterocyclic compounds containing two nitrogen atoms at 1 and 3 position. The chemistry of pyrimidines has become increasingly important as a result of recent developments in medicinal chemistry. Pyrimidine derivatives have been investigated extensively due to their great biological significance and as main constituent of nucleic acids. Pyrimidines and their derivatives are considered to be important for drugs and agricultural chemicals. They are also found to exhibit remarkable pharmacological activities such as anti-cancer, anti-tumor, anti-inflammatory and antifungal etc and are used widely as agrochemicals, pharmaceuticals, dyes, organic additives in electroplating of steel and in the polymerization process^{1,2}. Our interest in the preparation of

pharmacologically active compounds led us to synthesize the title compound and we report its crystal structure herein.

II. MATERIALS AND METHODS

Single crystal X-ray diffraction analysis was carried out to confirm crystalline quality and also to identify the universal lattice parameters using Bruker Kappa APEXII CCD diffractometer³. The MoK α radiation of wavelength ($\lambda = 0.71073$ Å) and multi-scan technique for absorption were used for data collection. The lattice parameters were determined by the least-squares method on the basis of all reflections with $F^2 > 2\sigma(F^2)$


To an ethanolic solution of ethyl aceto acetate (2 ml, 0.01 mol), 2-hydroxy-4-methoxybenzaldehyde (1.5 mL, 0.01 mol) and thiourea (2.3 g, 0.03 mol) were added followed by CeCl₃·7H₂O (931 mg). The reaction mixture was taken in a round-bottom flask and refluxed for 8 h. Then the reaction mixture was cooled and poured into crushed ice taken in a beaker with constant stirring. The solid separated out was filtered, washed with ice-cold water and then recrystallized from hot ethanol to afford the product [yield: 85%; m.p. 417- 419 K].

A suitable single crystal of dimension 0.20 x 0.15 x 0.10 mm was selected for X-ray structure determination. The structures were solved by direct methods using SHELXS-97 and refined by a full-matrix least-squares procedure using the program SHELXL-97⁴. The software used for molecular graphics are ORTEP-3 for windows⁵ and PLATON⁶. The software used to prepare material for publication is WinGX publication routines⁷. All non-hydrogen atoms were assigned anisotropic displacement parameters in the refinement. H atoms were placed in geometrically idealized positions and refined as

riding on their parent, atoms with C-H distances fixed in the range 0.93-0.98 Å and N-H=0.86 Å with $U_{iso}(H)=1.5U_{eq}(CH_3)$ and $1.2U_{eq}(CH_2,CH,NH)$. The chemical structure of the title compound 1 is shown in **Scheme I**. Molecular structure of the title compound showing the atomic numbering scheme is shown in **Figure I**. The crystallography details for the structure determination of the compound are displayed in **Table I** and hydrogen bond geometry are listed in **Table II** respectively.

III. RESULT AND DISCUSSION

The chemical structure of the title compound as shown in **Scheme I**.



Scheme I

The dihydropyrimidine ring adopts boat conformation, with puckering parameters are $q_2 = 0.294$ Å, $q_3 = 0.073$ Å, $Q = 0.303$ Å, $\Theta = 76.1(4)^\circ$ and $\Phi = 47.3(4)^\circ$. The benzene ring is planar with r.m.s deviation of 0.0076 Å and makes a dihedral angle of $80.29(8)^\circ$ with the dihydropyrimidine ring. The ethyl acetate group attached to the pyrimidine ring shows an extended conformation [torsion angle = $C9-C12-O3-C13 = 179.27(2)^\circ$].

Table I. Crystal data and structure refinement parameters

Formula weight	322.37
Crystal shape, color	Block, colorless
Temperature	293 K
Wavelength	0.71073 Å
Crystal system	Triclinic
Space group	P-1

Unit cell dimensions	$a = 8.474(5)$ Å $b = 9.402(5)$ Å $c = 11.239(5)$ Å $\alpha = 98.133^\circ$ $\beta = 108.117^\circ$ $\gamma = 108.575^\circ$
Volume	$777.4(7)$ Å ³
Z	2
Density (calculated)	1.377 Mg/m ³
Absorption coefficient	0.228 mm ⁻¹
F(000)	340
Crystal size	$0.20 \times 0.15 \times 0.10$ mm
Theta range for data collection	2° to 26.6°
Index ranges	$-10 \leq h \leq 10$ $-11 \leq k \leq 11$ $-14 \leq l \leq 14$
Reflection collected	11409
Max. and min. transmission	0.978 and 0.946
Refinement method	Full-matrix least-squares on F^2
Data / restraints / parameters	3233/0/203
Goodness-of-fit on F^2	1.087
R indices(all data)	$R_1 = 0.024$
Final R indices [$I > 2\sigma(I)$]	$R = 0.037$ $wR_2 = 0.108$
Largest diff. peak and holes	0.31 e.Å ⁻³ and -0.22 e.Å ⁻³

In the crystal the molecules are linked via a pair of C—H...S hydrogen bonds forming an inversion dimmers with $R_2^2(12)$ ring motif and form a chain parallel to the ca plane (**Figure II**).

V. SUPPLEMENTARY DATA

CCDC 1448392 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

REFERENCES

- [1] Vaisalini N B, Rao N V, .Harika V B M L , Desu P K and Nama S, *Int. J. pharm. chem. Res.*, 1, **2012**, 2278 – 8700.
- [2] Sharma A., khare R, kumar V, Gupta G K and Beniwal V, *Int. J. Pharm. Pharm. Sci.*, 6, **2014**, 171– 175.
- [3] Bruker, APEX2,SADABAS, SAINT and XPREP. Bruker AXS Inc, Madison, Wisconsin, USA, **2008**.
- [4] Sheldrick G M, *Acta Cryst.*, A64, **1997**, 112 – 122.
- [5] Farrugia L J, *J. Appl. Cryst.*, 45, **2012**, 849-854.
- [6] Spek A L, *Acta Cryst.*, D65, , **2009**, 148 - 155.
- [7] Farrugia L J, *J. Appl. Cryst.*, 32, **1999**, 837 – 838.




Figure I

The molecular structure of the title compound with displacement ellipsoids drawn at the 50% probability level.




Figure II

Partial crystal packing diagram for the title compound, showing the $R_2^2(12)$ ring motifs. Hydrogen bonds are shown as dashed lines.

Table II - Hydrogen bond geometry (\AA , $^\circ$)

D—H...A	D—H	H...A	D...A	D—H...A
C17—H17A...S	0.96	2.87	3.781(4)	158

IV. CONCLUSION

We have synthesized the dihydropyrimidinones (DHPMS) derivative and characterized by single crystal X-ray diffraction analysis.